{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-109407","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.404300+00:00","generated_at":"2026-05-15T10:48:01.910127+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics closes exclusive worldwide license for HCW11-006; receives $7M upfront fee","bullets":["Total upfront fee of $7.0M: $3.5M cash plus $3.5M transferable equity interest in licensee Trimmune.","HCW eligible for development milestones, double-digit royalties on future sales, and proceeds from future transactions.","HCW has free option to recapture Americas rights after Phase 1 in China; Phase 1 expected H1 2027.","Trimmune granted option to license HCW9302 for China; additional payments due if option exercised."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-109407","json":"https://secwatch.observer/filing/0001193125-26-109407.json","markdown":"https://secwatch.observer/filing/0001193125-26-109407.md","text":"https://secwatch.observer/filing/0001193125-26-109407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/0001193125-26-109407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/hcwb-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:48:01.910127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}